Better antibody discovery using proteogenomics
The natural antibody response to immunological challenge is a rich source of therapeutic candidates. Current technologies, such as hybridoma and phage display, provide a limited and biased view into the diverse antibody repertoire. Our goal is to interrogate the repertoire directly to rapidly identify high-affinity antibodies for therapeutic and diagnostic applications.
Currently, antibody repertoire analysis utilizes next-generation sequencing of antibody transcripts from B-cells. These repertoires are a poor proxy for the collection of antibodies in serum that have been produced in response to infection or immunization.
At Digital Proteomics, we have developed Alicanto, a proteogenomic platform for antibody discovery that harnesses decades of technology development across genomics and proteomics. We corroborate the serum antibodies with the next-generation sequencing-derived repertoire to select high affinity monoclonal antibodies